alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › longitudinal

longitudinal

9 studies tagged longitudinal, dated 2012-07-02 to 2024-01-01. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Longitudinal Phospho-tau217 Predicts Amyloid Positron Emission Tomography in Asymptomatic Alzheimer's Disease 2024-01-01
  2. Longitudinal cerebrospinal fluid measurements show glial hypo- and hyperactivation in predementia Alzheimer's disease 2023-12-13
  3. Alzheimer's disease diagnostic accuracy by fluid and neuroimaging ATN framework 2023-07-12

Studies

9 studies carry this tag.

Date range

2012 to 2024

Top journals

  • Journal of neuroinflammation 2
  • Alzheimer's research & therapy 1
  • Brain : a journal of neurology 1
  • Brain communications 1
  • CNS neuroscience & therapeutics 1

8 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Longitudinal Phospho-tau217 Predicts Amyloid Positron Emission Tomography in Asymptomatic Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 60 out of 100. The journal of prevention of Alzheimer's disease 2024-01-01 Biomarkers

    An ECL immunoassay testing plasma P-tau217 accurately predicts amyloid PET positivity in cognitively unimpaired individuals.

  2. Longitudinal cerebrospinal fluid measurements show glial hypo- and hyperactivation in predementia Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 67 out of 100. Journal of neuroinflammation 2023-12-13 Biomarkers

    Cross-sectionally, CSF sTREM2, YKL-40, clusterin and fractalkine were higher only in groups with tau pathology, independent of amyloidosis (p < 0.001, A+/T+ or N+ and A-/T+ or N+, compared to A-/T-/N-).

  3. Alzheimer's disease diagnostic accuracy by fluid and neuroimaging ATN framework

    ✓ Peer-reviewed alzhub usefulness score 71 out of 100. CNS neuroscience & therapeutics 2023-07-12 Biomarkers

    Our findings suggest that plasma, CSF, and neuroimaging biomarkers differ considerably within the ATN framework; the most accurate target biomarkers for diagnosing AD were the CSF-A, neuroimaging-T, and neuroimaging-N within each ATN modality.

  4. Sex differences in Alzheimer's disease: plasma MMP-9 and markers of disease severity

    ✓ Peer-reviewed alzhub usefulness score 71 out of 100. Alzheimer's research & therapy 2022-11-02 Biomarkers

    MMP-9 may have more detrimental effects on AD-related pathological and cognitive changes in women.

  5. Matrix metalloproteinase 10 is linked to the risk of progression to dementia of the Alzheimer's type

    ✓ Peer-reviewed alzhub usefulness score 67 out of 100. Brain : a journal of neurology 2022-07-01 Biomarkers

    Alzheimer's disease has a long asymptomatic phase that offers a substantial time window for intervention.

  6. Association of plasma P-tau181 with memory decline in non-demented adults

    ✓ Peer-reviewed alzhub usefulness score 74 out of 100. Brain communications 2021-06-14 Biomarkers

    Mixed-effect models assessed rates of memory decline in relation to baseline plasma p-tau181, and whether plasma p-tau181 significantly predicted memory decline beyond widely available clinical and genetic data (age, sex, years of education, cardiovascular and metabolic conditions, and APOE ε 4 status).

  7. A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment

    ✓ Peer-reviewed alzhub usefulness score 53 out of 100. Journal of Alzheimer's disease : JAD 2018-01-01 Biomarkers

    Alzheimer's disease (AD) features a dynamic sequence of amyloid deposition, neurodegeneration, and cognitive impairment.

  8. Tau plasma levels in subjective cognitive decline: Results from the DELCODE study

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Scientific reports 2017-08-25 Biomarkers

    Previous studies have demonstrated increased tau plasma levels in patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI) due to AD.

  9. Inhibition of Src kinase activity attenuates amyloid associated microgliosis in a murine model of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 55 out of 100. Journal of neuroinflammation 2012-07-02 Biomarkers

    These data suggest that amyloid dependent microgliosis may be Src kinase dependent in vitro and in vivo.

All topic tags with their study counts